Important Reminder to Shareholders of Arrowhead Research Corporation of Upcoming Lead Plaintiff Deadline on December 9, 2014


NEW YORK, Nov. 14, 2014 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action has been commenced in the United States District Court for the Central District of California on behalf of purchasers of common stock of Arrowhead Research Corporation ("Arrowhead") (Nasdaq:ARWR) during the period of August 12, 2014 through October 8, 2014, inclusive (the "Class Period").

It is alleged that Arrowhead materially misstated clinical trial information from its experimental hepatitis B therapy ARC-520 by falsely suggesting that the Company's therapy was more effective than it actually was.

On October 8, 2014, Arrowhead released disappointing data from its ARC-520 therapy. On that same day, an article published on TheStreet.com reported that Arrowhead CEO Chris Anzalone and his team knew for months that ARC-520 dosed at 1 mg/kg and 2 mg/kg yielded only 0.2-log and 0.3-log reductions in hepatitis B viral load. Arrowhead executives led investors to believe that ARC-520 was more potent and achieved substantially larger viral load reductions in the range of 0.7 log or higher. On this news, shares of Arrowhead plummeted by $5.48 per share, or over 43%, to close at $7.03 per share.

If you purchased and incurred losses in Arrowhead Research Corporation common stock during the Class Period, you may move to be appointed as lead plaintiff by December 9, 2014. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Wolf Haldenstein, or other counsel of your choice, to serve as your counsel in this action.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has over 70 attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.  All e-mail correspondence should make reference to the "Arrowhead investigation."

Attorney Advertising.   Prior results do not guarantee or predict a similar outcome.



            

Contact Data